Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Champlin

Showing results (181-190 of 218) with videos related to

Pageof 22
Sort By:
Acta Haematologica|July 1, 2020
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid LeukemiaAmanda L Olson, Rima M Saliba, Betul Oran, et al.
British Journal of Haematology|November 29, 2024
Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplantCurtis Marcoux, Sarah Pasyar, Denái R Milton, et al.
American Journal of Hematology|August 28, 2023
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemiaTapan M Kadia, Farhad Ravandi, Matteo Molica, et al.
Transplantation and Cellular Therapy|May 9, 2021
Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled TrialSairah Ahmed, Qaiser Bashir, Roland Bassett, et al.
Blood|July 24, 2014
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHDAhmad Khoder, Anushruti Sarvaria, Abdullah Alsuliman, et al.
The Lancet. Oncology|December 8, 2015
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trialMichael L Wang, Hun Lee, Hubert Chuang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 24, 2015
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsMohamed Shanavas, Uday Popat, Laura C Michaelis, et al.
Blood Advances|May 13, 2020
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantationMonzr M Al Malki, Dongyun Yang, Myriam Labopin, et al.
British Journal of Haematology|September 7, 2022
Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplantHua-Jay J Cherng, Guofan Xu, Lei Feng, et al.
The New England Journal of Medicine|February 6, 2020
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsEnli Liu, David Marin, Pinaki Banerjee, et al.
Pageof 22

Showing results (181-190 of 218) with videos related to

Sort By:
Pageof 22
Acta Haematologica|July 1, 2020
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid LeukemiaAmanda L Olson, Rima M Saliba, Betul Oran, et al.
British Journal of Haematology|November 29, 2024
Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplantCurtis Marcoux, Sarah Pasyar, Denái R Milton, et al.
American Journal of Hematology|August 28, 2023
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemiaTapan M Kadia, Farhad Ravandi, Matteo Molica, et al.
Transplantation and Cellular Therapy|May 9, 2021
Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled TrialSairah Ahmed, Qaiser Bashir, Roland Bassett, et al.
Blood|July 24, 2014
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHDAhmad Khoder, Anushruti Sarvaria, Abdullah Alsuliman, et al.
The Lancet. Oncology|December 8, 2015
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trialMichael L Wang, Hun Lee, Hubert Chuang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 24, 2015
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsMohamed Shanavas, Uday Popat, Laura C Michaelis, et al.
Blood Advances|May 13, 2020
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantationMonzr M Al Malki, Dongyun Yang, Myriam Labopin, et al.
British Journal of Haematology|September 7, 2022
Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplantHua-Jay J Cherng, Guofan Xu, Lei Feng, et al.
The New England Journal of Medicine|February 6, 2020
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsEnli Liu, David Marin, Pinaki Banerjee, et al.
Pageof 22